Citius Oncology, Inc. CTOR

CTOR Company Overview

Citius Oncology, Inc. (NASDAQ: CTOR) is a specialty oncology company focused on the development and commercialization of oncology therapeutics, with an emphasis on immunotherapy and targeted cancer treatments. The company was formed to advance oncology-focused assets associated with Citius Pharmaceuticals and operates within the biopharmaceutical and oncology therapeutics industries. Its primary strategic focus has centered on advancing late-stage oncology candidates intended to address unmet medical needs in hematologic malignancies and related cancer indications.

A key component of the company’s business strategy has been the development and planned commercialization of LYMPHIR™ (denileukin diftitox-cxdl), an engineered interleukin-2 receptor-targeted immunotherapy indicated for certain relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients. The company’s positioning is tied to targeting niche oncology indications with limited treatment alternatives, potentially enabling focused commercialization efforts in specialty oncology markets. Citius Oncology emerged as part of a broader restructuring and strategic separation from Citius Pharmaceuticals, Inc., which historically incubated and developed several specialty pharmaceutical and oncology assets.